The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
Abstract
PURPOSE: To report the authors' experience after intravitreal bevacizumab (Avastin, Genentech) injection in patients with macular edema (ME) secondary to branch retinal vein occlusive disease (BRVO). METHODS: A consecutive retrospective review of patients with ME secondary to BRVO who were treated with intravitreal bevacizumab (1.25 mg/0.05 mL). Patients underwent complete ophthalmic evaluation, which included nonstandardized Snellen visual acuity testing, optical coherence tomography (OCT), and/or angiographic testing at baseline and follow-up visits. RESULTS: There were 27 consecutive patients who received intravitreal bevacizumab injections. The mean length of follow-up was 5.3 months (median 6 months, range 3-8 months). The mean visual acuity improved from 20/200(-) at baseline to 20/100(-) at 1 month and 20/100(+) at 3 months and last follow-up (P < 0.001). The mean central 1 mm macular thickness was 478 microm at baseline and decreased to 310, 336, and 332 microm at 1 month, 3 months, and last follow-up (P < 0.001). Patients received an average of two injections (range one to three). No adverse side effects were observed following injections. CONCLUSION: The observed anatomic (by ophthalmic examination, OCT, and/or fluorescence angiography) and visual acuity improvements and lack of serious adverse side effects after intravitreal bevacizumab injection demonstrates, in principle, the potential of bevacizumab for the treatment of ME in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Cited by
Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities
Rehak, J., & Rehak, M. (2008) · Current Eye Research · doi:10.1080/02713680701851902 · Cited by 429
Campochiaro, P. A., Hafiz, G., Shah, S. M., Nguyen, Q. D., Ying, H., Do, D. V., Quinlan, E., Zimmer-Galler, I., Haller, J. A., Solomon, S. D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.10 · Cited by 321
Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab
Mozayan, A., & Farah, S. (2013) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20121221-08 · Cited by 22
Metadata
- Authors
- RABENA, M. D., PIERAMICI, D. J., CASTELLARIN, A. A., NASIR, M. A., & AVERY, R. L.
- Venue
- Retina
- Published
- 2007-04
- Volume
- 27
- Issue
- 4
- Pages
- 419-425
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1989523910
- Cited by
- 245
- References
- 1
- FWCI
- 30.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. https://app.cochat.ai/papers/10.1097/iae.0b013e318030e77e
- The paper
- RABENA, M. D., PIERAMICI, D. J., CASTELLARIN, A. A., NASIR, M. A., & AVERY, R. L. (2007). INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. Retina. https://doi.org/10.1097/iae.0b013e318030e77e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.